Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy Improves Survival in Unresectable Esophageal Cancer: a systematic review, meta-analysis, and network meta-analysis - Scorecard - MDSpire
Advertisement
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy Improves Survival in Unresectable Esophageal Cancer: a systematic review, meta-analysis, and network meta-analysis
Clinical Scorecard: Combination of Induction Immunochemotherapy and Concurrent Chemoradiotherapy Enhances Survival Outcomes in Patients with Unresectable Esophageal Cancer: A Systematic Review and Meta-Analytical Approach
At a Glance
Category
Detail
Condition
Unresectable Esophageal Cancer
Key Mechanisms
Combination of immunotherapy with concurrent chemoradiotherapy (CCRT)
Target Population
Patients with unresectable esophageal cancer
Care Setting
Oncology
Key Highlights
Induction immunochemotherapy plus CCRT (ICT-CCRT) significantly enhances overall survival (OS)
CCRT plus consolidation immunotherapy (CCRT-IO) improves progression-free survival (PFS)
ICT-CCRT ranks highest for both OS and PFS in network meta-analysis
Insufficient randomized controlled trials exist to validate efficacy
CCRT-IO shows consistent PFS benefits across analyses
Guideline-Based Recommendations
Diagnosis
Assess unresectable esophageal cancer using imaging and endoscopic evaluations
Management
Consider ICT-CCRT for improved OS in unresectable EC patients
Utilize CCRT-IO for PFS benefits
Monitoring & Follow-up
Regularly evaluate patient response to treatment through imaging and clinical assessments
Risks
Monitor for potential adverse effects of combined therapies
Patient & Prescribing Data
Patients diagnosed with unresectable esophageal cancer
Combination therapies may enhance survival outcomes but require further validation
Clinical Best Practices
Integrate immunotherapy with CCRT for eligible patients
Conduct thorough assessments to tailor treatment plans
Cancer care today is more advanced, more personalized, and more effective than ever before, and Radiation Oncology plays a central role in that progress.
Boston magazine has named more than 145 physicians affiliated with Dana-Farber Cancer Institute to its annual "Top Doctors" guide. Drawing from a Castle Connolly Medical Ltd. physician database, the Boston magazine Top Doctors™ list draws from hundreds of Boston-area physicians in many medical specialties
